REGN - リジェネロン・ファ―マシュ―ティカルズ （Regeneron Pharmaceuticals Inc.）

Biopharma stocks were not immune to the broader market downturn seen for much of 2022. The iShares Biotechnology ETF (NASDAQ: IBB ), which is heavily weighted with large-cap biotech companies, has lost 13.2% compared to a steeper 27.8% pullback by the SPDR S&P Biotech (NYSE: XBI ). What Happened: This clearly suggests that the sell-off is more acute in the small-cap space. More importantly, the declines of the year came on top of sharp losses experienced by the sector in 2021. See Also: Best Biotech Socks Right Now The year was a forgettable one from the fundamental perspective too. Drug innovation dwindled, as evident from the drop in new molecular entity approvals from 50 in 2021 to 34 in 2022. The alleviation of the COVID-19 situation did not bode well for vaccine manufacturers and their stocks pulled back in line with the reduced forecast for vaccine sales. December proved to be a mixed month for FDA approvals. Mirati Therapeutics Inc. ’s (NASDAQ: MRTX ) adagrasib, a KRAS G12C inhibitor, received the nod for treating a certain type of lung cancer.

Japanese regulators have granted marketing authorization to Regeneron''s (REGN) Libtayo (cemiplimab) for advanced or recurrent cervical cancer.

BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Regeneron Pharmaceuticals (REGN) announced the Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for Libtayo…

PARIS (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi said that the New England Journal of Medicine has published results from a positive Phase 3 trial showing adults and adolescents …

TARRYTOWN, N.Y. , Dec. 19, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 . The presentation is scheduled for 9:00 a.m. Pacific Time ( 12:00 p.m.

https://www.investing.com/news/pro/regeneron-director-tessierlavigne-files-to-sell-51m-in-stock-432SI-2903099

A regulatory filing for prurigo nodularis is under review by the European Medicines Agency. The post Regeneron announces FDA approval for Dupixent to treat prurigo nodularis appeared first on Westfair Communications .

This approval makes Dupixent the first and only medicine available in the US for the treatment of prurigo nodularis, a chronic and debilitating skin disease. A fully human The post US FDA approves Sanofi and Regeneron’s Dupixent to treat prurigo nodularis appeared first on Pharmaceutical Business review .

The FDA has approved Dupixent, developed by Regeneron (REGN) and Sanofi (SNY) (SNYNF) (GCVRX), for adults with prurigo nodularis, a chronic, inflammatory skin condition. The…

PARIS (dpa-AFX) - The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis, Regeneron Pharmaceuticals Inc. (REGN) and Sano…

Due to the lack of effectiveness against omicron and the variants, World Health Organization (WHO) no longer recommends using two COVID-19 antibody therapies. WHO experts said they strongly advised against using GSK plc (NYSE: GSK ) / Vir Biotechnology Inc''s (NASDAQ: VIR ) sotrovimab and Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) / Roche Holdings AG''s (OTC: RHHBY ) antibody cocktail casirivimab-imdevimab. The recommendation comes as part of a suite of recommendations published in the British Medical Journal . The two therapies designed to work by binding to the … Full story available on Benzinga.com

Intellia Therapeutics (NTLA) and Regeneron (REGN) announced Friday that NTLA-2001, a genome editing therapy targeted at heart-related issues in transthyretin ((ATTR)) amyloidosis, cut…

WASHINGTON (dpa-AFX) - Intellia Therapeutics, Inc. (NTLA) and Regeneron Pharmaceuticals, Inc. (REGN) reported positive interim results from an ongoing phase 1 clinical trial of NTLA-2001, an inves…

The World Health Organization in its updated guidelines recommended against the use of GSK (GSK) and Vir Biotechnologys'' (VIR) sotrovimab Regeneron Pharmaceuticals'' (REGN) antibody…

LONDON, United Kingdom – Two COVID-19 antibody therapies are no longer recommended by the World Health Organization (WHO), on the basis that Omicron and the variant’s latest offshoots have likely rendered them obsolete. The two therapies – which are designed to work by binding to the spike protein of SARS-CoV-2 to neutralise the virus’ ability to infect cells – were some of the first medicines developed early in the pandemic. The virus has since evolved, and mounting evidence from lab tests suggests the two therapies – sotrovimab as well as casirivimab-imdevimab – have limited clinical activity against the latest iterations of the virus. As a result, they have also fallen out of favour with the US health regulator. On Thursday, September 15, WHO experts said they strongly advised against the use of the two therapies in patients with COVID-19, reversing previous conditional recommendations endorsing them, as part of a suite of recommendations published in the British Medical Journal. GSK and partner Vir Biotechnology’s sotrovimab – which has generated billions in sales and became one of the British drugmaker’s top sellers last year – was pulled off the US market by the US Food and Drug Administration (FDA) in April.